Is high-frequency repetitive transcranial magnetic stimulation of the left primary motor cortex superior to the stimulation of the left dorsolateral prefrontal cortex in fibromyalgia syndrome?
Somatosensory & Motor Research · 02.01.2019 · 36 (1) · 56-62
DOI: 10.1080/08990220.2019.1587400 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Somatosensory & Motor Research, online erschienen am 08.04.2019. Verfasst von Elif Umay Altas und 3 weiteren Autor:innen. Beteiligte Einrichtung: a Physical Medicine and Rehabilitation, Izmir Ataturk Egitim ve Arastirma Hastanesi , Katip Celebi University Ataturk Education and Research Hospital…. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To investigate effectiveness of two different high-frequency repetitive transcranial magnetic stimulation (rTMS) protocols on pain, fatigue, quality of life (QoL) and depression in female patients with fibromyalgia. METHODS: Thirty patients were randomized into three groups. Fifteen sessions of 10 Hz (90% resting motor threshold-RMT, 1200 pulses) rTMS were applied to left primary motor cortex and left dorsolateral prefrontal cortex (DLPFC) in Group M1 (n:10) and Group DLPFC (n:10), respectively. Group sham (n = 10) received 15 sessions of sham rTMS over 3 weeks. Visual Analogue Scale, Fibromyalgia Impact Questionnaire, Fatigue Severity Scale, Short-form 36, and Beck Depression Inventory were assessed at baseline and at the end of the treatments by a blinded-experienced assessor. RESULTS: Significant improvements in pain, QoL, and depression scores were observed in three groups. However, improvements in depression, physical functioning, physical role functioning, and general health perceptions were greater in active rTMS groups than in sham group. Emotional role functioning was only improved in Group M1. The decrease in VAS scores was significantly greater in Group M1 when compared to sham group. Change in physical role functioning was significantly greater in Group DLPFC than in Group M1. CONCLUSIONS: Significant improvements in physical role functioning, physical functioning, depression, and general health perceptions were achieved in active rTMS groups. Further clinical studies on larger samples involving both sexes with longer follow-up durations are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- a Physical Medicine and Rehabilitation, Izmir Ataturk Egitim ve Arastirma Hastanesi , Katip Celebi University Ataturk Education and Research Hospital , Izmir , Turkey.
- b Physical Medicine and Rehabilitation , Izmir Katip Celebi Universitesi , Izmir , Turkey.
- c Department of Psychiatry , Katip Çelebi University , Izmir , Turkey.
- d Physical Medicine and Rehabilitation , Izmir Katip Celebi Universitesi , Izmir , Turkey.
ORCID-Profile: Elif Umay Altas, Ayhan Askin, Lütfullah Beşiroğlu, Aliye Tosun
Zitieren
APA
Altas, E. U., Askin, A., Beşiroğlu, L., & Tosun, A. (2019). Is high-frequency repetitive transcranial magnetic stimulation of the left primary motor cortex superior to the stimulation of the left dorsolateral prefrontal cortex in fibromyalgia syndrome?. Somatosensory & Motor Research, 36(1), 56-62. https://doi.org/10.1080/08990220.2019.1587400
Vancouver
Altas EU, Askin A, Beşiroğlu L, Tosun A. Is high-frequency repetitive transcranial magnetic stimulation of the left primary motor cortex superior to the stimulation of the left dorsolateral prefrontal cortex in fibromyalgia syndrome?. Somatosensory & Motor Research. 2019;36(1):56-62. doi:10.1080/08990220.2019.1587400
BibTeX
@article{Altas2019,
author = {Altas, Elif Umay and Askin, Ayhan and Beşiroğlu, Lütfullah and Tosun, Aliye},
title = {Is high-frequency repetitive transcranial magnetic stimulation of the left primary motor cortex superior to the stimulation of the left dorsolateral prefrontal cortex in fibromyalgia syndrome?},
journal = {Somatosensory & Motor Research},
year = {2019},
volume = {36},
number = {1},
pages = {56--62},
doi = {10.1080/08990220.2019.1587400}
}
EUVIMED